387P Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
作者
H. Horinouchi,J.W. Goldman,B.C. Cho,Pascale Tomasini,M. Dunbar,D. Hoffman,Apurvasena Parikh,Vincent Blot,D. Ross Camidge
出处
期刊:Annals of Oncology [Elsevier BV] 日期:2022-11-01卷期号:33: S1592-S1592被引量:6